PReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis

類似資料

• PReS-FINAL-2111: Cytomegalovirus, Epstein Barr virus and Varicella-Zoster virus infections in children with juvenile idiopathic arthritis treated with biologics
  著者:: Remy Piccolo, V, 等
  出版事項: (2013)
• Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent
  著者:: Woerner, A, 等
  出版事項: (2015)
• PReS-FINAL-2043: Cardiac involvement in juvenile idiopathic arthritis
  著者:: Rossetto, E, 等
  出版事項: (2013)
• PReS-FINAL-2109: Genetic variations in patients with juvenile idiopathic arthritis and uveitis
  著者:: Reinards, TH, 等
  出版事項: (2013)
• PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
  著者:: Ruperto, N, 等
  出版事項: (2013)